NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis $70.84 +2.24 (+3.27%) Closing price 11/9/2026 04:00 PM EasternExtended Trading$77.50 +6.66 (+9.40%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tarsus Pharmaceuticals Stock (NASDAQ:TARS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tarsus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$67.45▼$71.2050-Day Range$67.52▼$90.7852-Week Range$53.89▼$91.53Volume1.05 million shsAverage Volume1.01 million shsMarket Capitalization$3.49 billionP/E RatioN/ADividend YieldN/APrice Target$104.57Consensus RatingModerate Buy Company Overview Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company’s work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions. Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention. Founded in 2016 and based in Irvine, California, Tarsus is led by co-founder, president and chief executive officer Bobak Azamian. The company’s commercial activities have included bringing XDEMVY to the U.S. market.AI Generated. May Contain Errors. Read More Tarsus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreTARS MarketRank™: 3.599368652205 of 5 starsTarsus Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 184th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTarsus Pharmaceuticals has a consensus price target of $104.57, representing about 47.6% upside from its current price of $70.84.Amount of Analyst CoverageTarsus Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($12.10) to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 33.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.87% of the float of Tarsus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 5.71.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently decreased by 5.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.23 News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Tarsus Pharmaceuticals this week, compared to 5 articles on an average week.MarketBeat FollowsOnly 1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,004,227.00 in company stock.Percentage Held by Insiders9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARS Stock News HeadlinesFY2026 Earnings Estimate for TARS Issued By HC WainwrightNovember 8 at 1:13 AM | americanbankingnews.comTarsus Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 7 at 6:50 PM | seekingalpha.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 10 at 1:00 AM | Weiss Ratings (Ad)Is Raised Revenue Outlook Altering The Investment Case For Tarsus Pharmaceuticals (TARS)?November 6, 2026 | finance.yahoo.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Gets Price Target Increase from HC WainwrightNovember 6, 2026 | americanbankingnews.comIs Tarsus Pharmaceuticals (TARS) Below Fair Value On Cash Flow?November 6, 2026 | finance.yahoo.comTarsus Pharmaceuticals (TARS) Could Be 31% Undervalued Following Record Q3 SalesNovember 5, 2026 | finance.yahoo.comTarsus to Participate in Upcoming Investor ConferencesNovember 5, 2026 | globenewswire.comSee More Headlines TARS Stock Analysis - Frequently Asked Questions How have TARS shares performed this year? Tarsus Pharmaceuticals' stock was trading at $81.88 on January 1st, 2026. Since then, TARS stock has decreased by 13.5% and is now trading at $70.84. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its quarterly earnings results on Tuesday, November, 3rd. The company reported ($14.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.46) by $12.94. The firm had revenue of $194.57 million for the quarter, compared to analyst estimates of $187.83 million. Tarsus Pharmaceuticals had a negative trailing twelve-month return on equity of 24.51% and a negative net margin of 102.93%. Read the conference call transcript. When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $88 million in an initial public offering on Friday, October 16th 2020. The company issued 5,500,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (1.40%), Allspring Global Investments Holdings LLC (0.31%), Russell Investments Group Ltd. (0.22%) and Commonwealth Equity Services LLC (0.14%). Insiders that own company stock include Bobak R Azamian, William J Phd Link, Seshadri Neervannan, Bryan Wahl, Jeffrey S Farrow, Aziz Mottiwala, Dianne C Whitfield, Andrew D Goldberg, Elizabeth Yeu Lin, Jose M Trevejo and Katherine Goodrich. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tarsus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Micron Technology (MU), CrowdStrike (CRWD), Salesforce (CRM) and NextEra Energy (NEE). Company Calendar Last Earnings11/03/2026Today11/10/20263rd Annual Guggenheim Healthcare Innovation Conference11/10/202638th Annual Healthcare Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TARS's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TARS CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees370Year Founded2017Price Target and Rating Average Price Target for Tarsus Pharmaceuticals$104.57 High Price Target$116.00 Low Price Target$97.00 Potential Upside/Downside+47.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($15.19) Trailing P/E RatioN/A Forward P/E Ratio98.39 P/E GrowthN/ANet Income-$66.42 million Net Margins-102.93% Pretax Margin-101.21% Return on Equity-24.51% Return on Assets-12.40% Debt Debt-to-Equity Ratio0.70 Current Ratio1.96 Quick Ratio3.17 Sales & Book Value Annual Sales$451.36 million Price / Sales7.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book33.57Miscellaneous Outstanding Shares49,310,000Free Float44,553,000Market Cap$3.49 billion OptionableOptionable Beta0.34 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:TARS) was last updated on 11/9/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWe flagged Marvell at $80. It's up 251%.On Feb. 7, 2026, Street Sheet Research members saw Marvell (NASDAQ: MRVL) at $80.28, with a $118 target from N...The Street Sheet | SponsoredIPO mania is back - here's the income play I'm watching closelySpaceX, Anthropic, and OpenAI are leading a new wave of blockbuster IPOs. Tim Plaehn found a quiet fund that l...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
